Shingrix Gets China Nod But Won’t Launch Until 2020 Amid Strong Demand

 
• By Brian Yang

Following a priority review, Shingrix may become the next hit vaccine in China as millions seek preventative care, but GSK is being cautious over supply plans.

A selective focus at the end of syringe while needle was injected into deltoid muscle and using the cotton to stop bleeding while pulling the needle out
GSK'S SHINGRIX COULD BECOME BEST-SELLING VACCINE IN CHINA • Source: Shutterstock

More from Vaccines

More from Pink Sheet